Is Evaxion Biotech A/S (EVAX) a Buy, Sell, or Hold?
NASDAQ : EVAX
Evaxion Biotech A/S
$3.17 USD
$0.07 (2.26%)
- Volume
- 21.05K
- Average Volume
- 24.91K
- Market Capitalization
- $20.02M
- P/E Ratio
- -2.07
- Dividend Yield
- 0.00%
- Price Target
- $9.50
- Year High
- $12.15
- Year Low
- $2.52
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.00
Company Overview
NASDAQ
Helen Katrina Tayton-Martin
Biotechnology
Healthcare
EVAX
46
DK
USD
Liquidity Metrics
0.00
0.00
0.00
0.00
0.00
Sales & Valuation
$7.53M
2.66
2.00
0.00
0.00
Profitability
-$1.21
-$7.71M
-129.63%
-142.01%
-73.56%
-41.28%
P/E Metrics
-2.07
-0.01
-0.01
Analyst Price Target & Rating
$9.50
$10.00
$9.00
1/5
4 Analysts
-66.63%
Financial Health Scores
-7.06
2/9
$18.44M
$23.64M
$10.44M
-$10.87M
Key Metrics (TTM)
$1.14M
0.15
-0.10
0.00
-73.56%
-35.48%
-37.75%
0.00%
0 days
Company Executives
| Name | Title |
|---|---|
| Helen Katrina Tayton-Martin | Chief Executive Officer |
| Benjamin Ole Wolthers | Vice President of Clinical Development |
| Thomas Frederik Schmidt | Chief Financial Officer |
| Birgitte Rono | Chief Scientific Officer & COO |
| Andreas Holm Mattsson | Founder & Chief AI Officer |
Poll Results
No votes yet today — be the first to share your view!
About Evaxion Biotech A/S (NASDAQ:EVAX) Stock
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark. ...
2026-07-17 07:15:00
COPENHAGEN, Denmark, July 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will present three-year clinical efficacy data from its phase 2 trial with personalized cancer vaccine candidate EVX-01 at the European Society for Medical Oncology (ESMO) Congress 2026 to be held in Madrid, Spain, from October 23-27, 2026.
Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1
2026-07-12 09:30:00
COPENHAGEN, Denmark, July 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, presents new data further supporting the multi-component concept of its cytomegalovirus (CMV) vaccine program EVX-V1.
2026-07-01 08:00:00
COPENHAGEN, Denmark, July 1, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will present new preclinical data for vaccine candidate EVX-V1 in a poster session at the International Herpesvirus Workshop (IHW) 2026 taking place in Montreal, Canada, July 11-15, 2026.
Evaxion receives Prix Galien UK Award for Best digital health solution
2026-06-12 03:00:00
COPENHAGEN, Denmark, June 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, has been awarded the 2026 Prix Galien UK Award for Best digital health solution for AI-Immunology™.
2026-06-11 02:00:00
COPENHAGEN, Denmark, June 11, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML). Developed with AI-Immunology™, EVX-04 targets multiple non-conventional endogenous retrovirus (ERV) tumor antigens from the dark genome.
2026-05-12 09:30:00
COPENHAGEN, Denmark, May 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will announce the functional characterization of EVX-04, an off-the-shelf therapeutic acute myeloid leukemia (AML) vaccine, in a poster presentation at the European Hematology Association (EHA) 2026 Congress taking place in Stockholm, Sweden, June 11-14, 2026.
Frequently Asked Questions
-
What is the current Evaxion Biotech A/S (EVAX) stock price?
-
Evaxion Biotech A/S(NASDAQ:EVAX) stock price is $3.17 in the last trading session. During the trading session, EVAX stock reached the peak price of $12.15 while $2.52 was the lowest point it dropped to. The percentage change in EVAX stock occurred in the recent session was 2.26% while the dollar amount for the price change in EVAX stock was $0.07.
-
EVAX's industry and sector of operation?
-
The NASDAQ listed EVAX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of EVAX?
-
Helen Katrina Tayton-Martin | Chief Executive Officer
Benjamin Ole Wolthers | Vice President of Clinical Development
Thomas Frederik Schmidt | Chief Financial Officer
Birgitte Rono | Chief Scientific Officer & COO
Andreas Holm Mattsson | Founder & Chief AI Officer -
How many employees does EVAX have?
-
Number of EVAX employees currently stands at 46. EVAX operates from Dr. Neergaards Vej, Horsholm, ND 2970, DK.
-
Link for EVAX official website?
-
Official Website of EVAX is: https://evaxion.ai
-
How do I contact EVAX?
-
EVAX could be contacted at phone #45 53 53 18 50 and can also be accessed through its website. EVAX operates from Dr. Neergaards Vej, Horsholm, ND 2970, DK.
-
How many shares of EVAX are traded daily?
-
The average number of EVAX shares traded daily for last 3 months was 24.91K.
-
What is the market cap of EVAX currently?
-
The market value of EVAX currently stands at $20.02M with its latest stock price at $3.17